Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23667141 | 0.83 | MTNR1A (0.38) | MTNR1AMTNR1BCCR2L3MBTL1 | |
| SCHEMBL31370913 | 0.81 | CYP2D6 (0.36) | CCR2L3MBTL1 | |
| SCHEMBL20665989 | 0.79 | CCR2 (0.36) | CCR2L3MBTL1 | |
| SCHEMBL29866512 | 0.76 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL25272280 | 0.75 | PDCD1 (0.33) | L3MBTL1 | |
| SCHEMBL21290621 | 0.75 | PDCD1 (0.39) | CCR2L3MBTL1 | |
| SCHEMBL19817054 | 0.75 | GAA (0.40) | — | |
| SCHEMBL29866024 | 0.75 | GAA (0.40) | — | |
| SCHEMBL23314553 | 0.73 | CTSL (0.34) | — | |
| SCHEMBL12233371 | 0.72 | CCR2 (0.55) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | MTNR1A 186/4885MTNR1B 155/4885CCR2 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.